首页> 美国卫生研究院文献>other >Involvement of PDGF in Fibrosis and Scleroderma: Recent Insights from Animal Models and Potential Therapeutic Opportunities
【2h】

Involvement of PDGF in Fibrosis and Scleroderma: Recent Insights from Animal Models and Potential Therapeutic Opportunities

机译:PDGF在纤维化和硬皮病中的参与:近期动物模型的见解和潜在的治疗机会

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Fibrosis is the principal characteristic of the autoimmune disease known as scleroderma or systemic sclerosis (SSc). Studies published within the last three years suggest central involvement of platelet-derived growth factors (PDGFs) in SSc-associated fibrosis. PDGFs may also be involved in SSc-associated autoimmunity and vasculopathy. The PDGF signaling pathway is well understood and PDGF receptors are expressed on collagen-secreting fibroblasts and on mesenchymal stem and/or progenitor cells that may affect SSc in profound and unexpected ways. Although much work remains before we fully understand how PDGFs are involved in SSc, there is much interest in using PDGF inhibitors as a therapeutic approach to SSc.
机译:纤维化是称为硬皮病或全身性硬化症(SSc)的自身免疫疾病的主要特征。最近三年内发表的研究表明,血小板源性生长因子(PDGF)参与了与SSc相关的纤维化。 PDGF也可能与SSc相关的自身免疫和血管病变有关。 PDGF信号传导途径是众所周知的,PDGF受体在分泌胶原蛋白的成纤维细胞和间充质干细胞和/或祖细胞上表达,可能以深刻而出乎意料的方式影响SSc。尽管在我们完全理解PDGF如何参与SSc之前还有很多工作要做,但是使用PDGF抑制剂作为SSc的治疗方法仍引起了很多兴趣。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号